CA2439917A1 - Compositions having improved bioavailability of eletriptan - Google Patents

Compositions having improved bioavailability of eletriptan Download PDF

Info

Publication number
CA2439917A1
CA2439917A1 CA002439917A CA2439917A CA2439917A1 CA 2439917 A1 CA2439917 A1 CA 2439917A1 CA 002439917 A CA002439917 A CA 002439917A CA 2439917 A CA2439917 A CA 2439917A CA 2439917 A1 CA2439917 A1 CA 2439917A1
Authority
CA
Canada
Prior art keywords
inhibitor
eletriptan
measured
dosing
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439917A
Other languages
English (en)
French (fr)
Inventor
Michael John Humphrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439917A1 publication Critical patent/CA2439917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002439917A 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan Abandoned CA2439917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0105131.7 2001-03-01
GBGB0105131.7A GB0105131D0 (en) 2001-03-01 2001-03-01 Compositions having improved bioavailability
PCT/IB2002/000512 WO2002070070A2 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Publications (1)

Publication Number Publication Date
CA2439917A1 true CA2439917A1 (en) 2002-09-12

Family

ID=9909814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439917A Abandoned CA2439917A1 (en) 2001-03-01 2002-02-20 Compositions having improved bioavailability of eletriptan

Country Status (8)

Country Link
EP (1) EP1372785A2 (https=)
JP (1) JP2004529893A (https=)
AU (1) AU2002232061A1 (https=)
BR (1) BR0207751A (https=)
CA (1) CA2439917A1 (https=)
GB (1) GB0105131D0 (https=)
MX (1) MXPA03007836A (https=)
WO (1) WO2002070070A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709739D0 (en) * 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine

Also Published As

Publication number Publication date
JP2004529893A (ja) 2004-09-30
MXPA03007836A (es) 2003-12-08
AU2002232061A1 (en) 2002-09-19
EP1372785A2 (en) 2004-01-02
GB0105131D0 (en) 2001-04-18
WO2002070070A2 (en) 2002-09-12
BR0207751A (pt) 2004-03-09
WO2002070070A3 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US6579898B2 (en) Compositions having improved bioavailability
RU2355399C2 (ru) Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
JP3350061B2 (ja) エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
EP2146721B1 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
CN102458370A (zh) 用于眼科用途的表面药物递送系统
JP7781998B2 (ja) Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物
AU784100B2 (en) Method of increasing the bioavailability and tissue penetration of azithromycin
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
Szoka et al. Amphotericin B formulated in liposomes and lipid based systems: a review
CN113543781A (zh) 通过控制峰值血浆水平使用多西他赛的癌症治疗
Hosoe et al. Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs
CA2439917A1 (en) Compositions having improved bioavailability of eletriptan
EP1701699A2 (en) Pharmaceutical compositions
JP2019536769A (ja) 粘膜活性剤送達
Zhang et al. A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer
US20060141028A1 (en) Cyclosporin formulations
EP2654754B1 (en) Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
EP1563850A2 (en) Method of increasing the bioavailability and tissue penetration of azithromycin
Gubbins The systemically acting azoles
Herbrecht et al. Antifungal Therapy in Patients with Hematological Malignancies
HK1070840A1 (zh) 含有氮雜環丁烷衍生物的藥物組合物
HK1070840B (en) Pharmaceutical compositions based on azetidine derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead